Christopher Ho, MD
Hematology & Oncology · West Hills, CANPI 1972774958
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $51,978 of the $86,556 with a category attached, or 60.1%. 60 manufacturers reported payments, led by Foundation Medicine, Inc. at 44.6% of the total. Reporting peaked in 2021 at $20,493 and has fallen 50.6% since, to $10,119 in 2025. Among hematology & oncology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 802 payments — averaging $107.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Foundation Medicine, Inc.$39K
- AstraZeneca$18K
- Amgen$7K
- Pfizer$5K
- EMD Serono, Inc.$2K
- E.r. Squibb & Sons, L.L.C.$2K
- plus $13K from 54 others
Across 2 payments — averaging $322.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$645
What the payments were for
- Consulting fees$51,97860%
- Speaking & faculty fees$14,69517%
- Travel & lodging$1,7882%
- Food & beverage$17,58820%
- Education$5071%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FOUNDATIONONE CDX$38,567
- FOUNDATIONFOCUS$19,112
- FOUNDATIONONE HEME$19,112
- FOUNDATIONONE$19,112
- FOUNDATIONONE LIQUID$18,143
- IMFINZI$14,383
- Otezla$6,739
- ELREXFIO$3,030
- BAVENCIO$2,040
- IBRANCE$1,500
- FOUNDATIONACT$970
- ELIQUIS$125
- DUPIXENT$104
How this compares
$86,556 in reported general payments places this provider in the 90th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 42 | $758,829 |
| RevlimidLenalidomide | 40 | $702,328 |
| ZejulaNiraparib Tosylate | 12 | $676,938 |
| InlytaAxitinib | 23 | $510,340 |
| TagrissoOsimertinib Mesylate | 18 | $394,100 |
| OpdivoNivolumab | 25 | $388,063 |
| KeytrudaPembrolizumab | 28 | $304,958 |
| PomalystPomalidomide | 11 | $258,520 |
| Lenalidomide | 23 | $253,664 |
| CalquenceAcalabrutinib Maleate | 16 | $247,496 |
| VenclextaVenetoclax | 23 | $246,062 |
| AlecensaAlectinib Hcl | 12 | $223,588 |
| ImbruvicaIbrutinib | 12 | $196,347 |
| ProcritEpoetin Alfa | 32 | $108,690 |
| XgevaDenosumab | 34 | $101,807 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $805 | $758,82942 claims |
| Bristol Myers SquibbRevlimid | $331 | $702,32840 claims |
| GSKZejula | $363 | $676,93812 claims |
| E.r. Squibb & Sons, L.L.C.Opdivo, Pomalyst | $1,870 | $646,58336 claims |
| AstraZenecaTagrisso, Calquence | $17,929 | $641,59634 claims |
| PfizerInlyta, Eliquis | $5,448 | $604,117120 claims |
| MerckKeytruda | $778 | $304,95828 claims |
| AbbVieVenclexta | $104 | $246,06223 claims |
| Genentech USA, Inc.Alecensa | $1,076 | $223,58812 claims |
| Johnson & JohnsonProcrit, Xarelto | $611 | $125,40343 claims |
| AmgenXgeva | $7,395 | $101,80734 claims |
| Taiho Oncology, Inc.Lonsurf | $117 | $101,74720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in West Hills
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.